Efficacy, Safety and Tolerability of Denosumab in the Treatment of Rheumatoid Arthritis

NCT00095498 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 227

Last updated 2021-10-25

Study results available
· View outcomes & findings →

Summary

This study will determine the efficacy, safety, and tolerability of denosumab (AMG 162) in the treatment of Rheumatoid Arthritis (RA).

Conditions

Interventions

DRUG

placebo

placebo subcutaneous injection

DRUG

denosumab

For subcutaneous injection

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-11
Primary Completion
2007-04-01
Completion
2007-04-01

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00095498 on ClinicalTrials.gov